On July 1, 2014, Genentech entered into an agreement to acquire Seragon Pharmaceuticals, Inc., a privately held biotechnology company based in San Diego, California. Upon closing of this acquisition, Genentech will obtain rights to Seragon’s portfolio of investigational next-generation oral selective estrogen receptor degraders (SERDs), for the potential treatment of hormone receptor-positive breast cancer.
More than 150,000 women in the United States are diagnosed each year with hormone receptor-positive cancer, which hijacks hormones like estrogen to fuel the growth of cancer cells.
These investigational next-generation SERDs will
Investigational next-generation selective estrogen receptor degraders (SERDs) are a class of small molecules that may exert a big effect on a key driver of breast cancer.
Public research, private backing and companies like Genentech are all aspects of a life science "ecosystem" that work together, keeping the best science moving forward.